argenx NV ADR (ARGX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, argenx NV ADR (ARGX) has a cash flow conversion efficiency ratio of 0.056x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($407.80 Million) by net assets ($7.32 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also explore ARGX asset base for the complete picture of this company's asset base.
argenx NV ADR - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how argenx NV ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. For the full company profile with market capitalisation and key ratios, see ARGX stock market capitalisation.
argenx NV ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of argenx NV ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ING Groep N.V
MX:INGN
|
N/A |
|
Shanghai Pudong Development Bank Co Ltd
SHG:600000
|
0.255x |
|
Hess Corporation
NYSE:HES
|
0.113x |
|
Franco-Nevada Corporation
TO:FNV
|
0.057x |
|
Ambev SA ADR
NYSE:ABEV
|
0.149x |
|
GALDERMA GROUP AG
NYSE:GALDY
|
N/A |
|
HOLCIM NEW(U.ADR)1/5/SF2
F:HLB
|
N/A |
|
KBC GROEP N.V. ADR
F:KDB0
|
N/A |
Annual Cash Flow Conversion Efficiency for argenx NV ADR (2011–2025)
The table below shows the annual cash flow conversion efficiency of argenx NV ADR from 2011 to 2025. See argenx NV ADR (ARGX) net assets for net asset value and shareholders' equity analysis.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $7.32 Billion | $850.49 Million | 0.116x | +871.70% |
| 2024-12-31 | $5.50 Billion | $-82.75 Million | -0.015x | +85.33% |
| 2023-12-31 | $4.10 Billion | $-420.33 Million | -0.103x | +66.55% |
| 2022-12-31 | $2.81 Billion | $-862.81 Million | -0.307x | -28.06% |
| 2021-12-31 | $2.53 Billion | $-606.81 Million | -0.239x | -0.60% |
| 2020-12-31 | $1.67 Billion | $-398.46 Million | -0.238x | -285.30% |
| 2019-12-31 | $1.18 Billion | $151.63 Million | 0.128x | +228.46% |
| 2018-12-31 | $615.87 Million | $-61.59 Million | -0.100x | +5.62% |
| 2017-12-31 | $413.81 Million | $-43.84 Million | -0.106x | -163.35% |
| 2016-12-31 | $66.65 Million | $11.15 Million | 0.167x | +144.93% |
| 2015-12-31 | $40.82 Million | $-15.19 Million | -0.372x | -182.21% |
| 2014-12-31 | $48.26 Million | $-6.37 Million | -0.132x | +56.66% |
| 2013-12-31 | $29.97 Million | $-9.12 Million | -0.304x | +54.29% |
| 2012-12-31 | $16.65 Million | $-11.09 Million | -0.666x | -366.23% |
| 2011-12-31 | $27.90 Million | $-3.98 Million | -0.143x | -- |
About argenx NV ADR
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgarti… Read more